Meta-analysis of the rs243865 MMP-2 polymorphism and age-related macular degeneration risk

PLoS One. 2019 Mar 7;14(3):e0213624. doi: 10.1371/journal.pone.0213624. eCollection 2019.

Abstract

Purpose: Several researchers have suggested that the rs243865 (16q13-q21) polymorphism in the promoter region of the metalloproteinase-2 (MMP-2) gene could be associated with an increased risk of developing age-related macular degeneration (AMD). However, previous results remain inconclusive. To clarify this controversy, we conducted a meta-analysis of the relationship between rs243865 of MMP-2 and AMD.

Methods: We included 6 independent case-control studies involving 1,682 AMD patients and 2,295 healthy subjects. The association between the rs243865 polymorphism and AMD was examined by the overall odds ratio (OR) with a 95% confidence interval (CI). We used a recessive genetic model analysis, sensitivity analysis, and assessment of bias in our meta-analysis.

Results: Our results showed that there was no significant association between the variant T allele (p-value = 0.10, OR [95%CI] = 0.95 [0.82-1.10]) or the CT+TT genotype (p-value = 0.16, OR [95%CI] = 0.92 [0.76-1.12]) of rs243865 MMP-2 polymorphism and the presence of AMD.

Conclusions: The rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. The MMP-2 (-1306 C>T) promoter variant is unlikely to have a major role in AMD risk susceptibility.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alleles
  • Case-Control Studies
  • Female
  • Genes, Recessive
  • Genotype
  • Humans
  • Macular Degeneration / genetics*
  • Male
  • Matrix Metalloproteinase 2 / genetics*
  • Middle Aged
  • Models, Genetic
  • Odds Ratio
  • Polymorphism, Single Nucleotide*
  • Promoter Regions, Genetic
  • Risk Factors
  • Sensitivity and Specificity

Substances

  • MMP2 protein, human
  • Matrix Metalloproteinase 2

Grants and funding

This work was supported in part by a grant from the Consejería de Educación, Junta de Castilla y León, Fondos FEDER (VA077P17) (JCP) and from Gerencia Regional de Salud de Castilla y León (INT/M/06/18) (AJC).